Congress trades
Intellia Therapeutics, Inc. (NTLA)
About Intellia Therapeutics, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- John Leonard
- Employees
- 377
- Listed since
- May 6, 2016
- Market value
- $1.7B
- Price to earnings
- -
- Earnings per share
- -$3.00
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 6, 2026 | -$0.80 | -$0.80 | $7.7M | $13.0M | EPS in lineRevenue miss |
| Q1 FY2026reported May 11, 2026 | -$0.81 | -$0.92 | $15.0M | $13.8M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$0.83 | -$0.99 | $23.0M | $12.0M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$0.92 | -$1.02 | $13.8M | $12.2M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | -$0.99 | -$1.03 | $14.2M | $14.1M | EPS beatRevenue in line |
| Q1 FY2025reported May 8, 2025 | -$1.10 | -$1.26 | $16.6M | $11.9M | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 30, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| John M. Leonard, M.D.President, Chief Executive Officer | $708K | $2.4M | $1.9M | $5.1M |
| Edward J. Dulac IIIExecutive Vice President, Chief Financial Officer and | $526K | $848K | $794K | $2.2M |
| David Lebwohl, M.D.Executive Vice President, Chief Medical Officer | $536K | $776K | $672K | $2.0M |
| James Basta, J.D.Executive Vice President, General Counsel and Corporat | $494K | $719K | $634K | $1.8M |
| Birgit Schultes, Ph.D.Executive Vice President, Chief Scientific Officer | $475K | $676K | $589K | $1.7M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| ARK Investment Management LLC | $285.5M | 16,875,684 | +16.3% | 12.64% |
| Blackrock, Inc. | $260.7M | 15,409,023 | +26.8% | 11.54% |
| State Street Corp | $156.3M | 9,234,987 | +33.4% | 6.92% |
| Vanguard Portfolio Management LLC | $124.1M | 7,332,401 | +17.8% | 5.49% |
| D. E. Shaw & Co., Inc. | $109.0M | 6,443,323 | +12.5% | 4.83% |
| Vanguard Capital Management LLC | $102.0M | 6,028,586 | +18.6% | 4.52% |
| Two Sigma Investments, LP | $88.6M | 5,235,348 | +11.3% | 3.92% |
| FMR LLC | $80.8M | 4,773,034 | +130.9% | 3.58% |
| RA Capital Management, L.P. | $76.6M | 4,526,926 | +100.0% | 3.39% |
| Regeneron Pharmaceuticals, Inc. | $62.7M | 3,702,995 | 0.0% | 2.77% |
| Geode Capital Management, LLC | $61.4M | 3,631,061 | +27.3% | 2.72% |
| Arrowstreet Capital, Limited Partnership | $55.5M | 3,280,760 | +134.8% | 2.46% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in NTLA
10 disclosures of 10 on record · median 13d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Donald S. Beyer, Jr.Joint | Stock | Sale | $15,001 - $50,000 | -87.6%S&P +74.6% · vs S&P 500 -162.3% | Feb 28, 2022 | Mar 3, 2022 | 3d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -90.8%S&P +66.0% · vs S&P 500 -156.8% | Oct 29, 2021 | Oct 30, 2021 | 1d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -91.8%S&P +75.0% · vs S&P 500 -166.8% | Sep 20, 2021 | Oct 1, 2021 | 11d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -92.0%S&P +75.4% · vs S&P 500 -167.4% | Jul 21, 2021 | Aug 7, 2021 | 17d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -85.1%S&P +102.9% · vs S&P 500 -188.0% | Jan 15, 2021 | Jan 31, 2021 | 16d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -64.3%S&P +114.1% · vs S&P 500 -178.4% | Nov 18, 2020 | Dec 1, 2020 | 13d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -41.2%S&P +119.4% · vs S&P 500 -160.6% | Aug 26, 2020 | Sep 6, 2020 | 11d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -48.7%S&P +140.2% · vs S&P 500 -188.9% | Jul 10, 2020 | Aug 9, 2020 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -15.9%S&P +133.0% · vs S&P 500 -148.9% | Jan 14, 2020 | Feb 22, 2020 | 39d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -27.0%S&P +143.1% · vs S&P 500 -170.1% | Dec 9, 2019 | Dec 14, 2019 | 5d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded NTLA?
Donald S. Beyer, Jr. disclosed NTLA transactions in the filings shown here.
How quickly are NTLA trades disclosed?
Congressional disclosures took a median of 13 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.